Introduction
Relatively little is known about the genetic events important in the molecular pathogenesis and malignant progression of sporadic meningiomas (Weber et al., 1997) . The most common genetic event associated with meningioma tumorigenesis is chromosome 22q loss of heterozygosity (LOH) with the inactivation of the NF2 gene (Ruttledge et al., 1994; Gutmann et al., 1997; Huynh et al., 1997; Leone et al., 1999; Ueki et al., 1999) . Based on structural homology, the NF2 gene product, merlin, belongs to the Protein 4.1 family. Members of this family are characterized by the presence of a conserved FERM (Four.1 protein, Ezrin, Radixin, Moesin) domain at the N-terminus of the molecule (Chishti et al., 1998) . These molecules are hypothesized to function by linking cell surface glycoproteins to the actin cytoskeleton, and are important for the maintenance of cell shape (Tsukita et al., 1997) . While most FERM-containing proteins are involved in actin cytoskeleton-associated processes, a second member of the Protein 4.1 family, Protein 4.1B (NCBI Accession #NP_036439), has recently been implicated in meningioma formation . Similar to merlin, 4.1B LOH is a common genetic alteration in meningiomas, regardless of histological grade, suggesting that 4.1B inactivation, like NF2 loss, may also be an early event in meningioma tumorigenesis .
Previous studies in our laboratory have mapped the minimal region of Protein 4.1B required for growth suppression of human meningioma cell lines to a fragment containing residues M110 through S835, designated DAL-1. DAL-1 (Differentially expressed in Adenocarcinoma of the Lung) was originally discovered by differential display RT-PCR as a 750 bp gene fragment whose expression was absent in several nonsmall-cell lung carcinomas when compared to matched normal tissue (Tran et al, 1999) . This minimal growth suppression domain (DAL-1) is composed of four major predicted regions: (1) an N-terminal FERM domain, (2) a unique region (U2), (3) a spectrin-actin-binding domain, and (4) another unique region at the Cterminus (U3). Re-expression of DAL-1 in meningioma cells resulted in a suppression of cell proliferation, identical to full-length Protein 4.1B (Gutmann et al., 2001a) . To provide insight into the mechanism(s) underlying Protein 4.1B growth suppression, efforts have focused on characterizing potential interacting proteins that might mediate the Protein 4.1B growth inhibitory signal. Protein 4.1B interacts with CD44 (Robb et al., 2003) , bII-spectrin (Gutmann et al., 2001a; Gimm et al., 2002 ), 14-3-3 b, g, and Z , Protein arginine N-methyltransferase 3 (PRMT3, Robb et al., 2003; Singh et al., manuscript in preparation) , and the membrane proteins Caspr/paranodin and Caspr2 (Denisenko-Nehrbass et al., 2003) . In contrast, Protein 4.1B does not interact with several merlin-binding proteins, including schwannomin interacting protein-1 (SCHIP-1; Goutebroze et al., 2000) and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), which has been implicated in merlin growth suppression (Scoles et al., 2000; Gutmann et al., 2001b; Scoles et al., 2002; Sun et al., 2002) .
The 14-3-3 family of proteins consists of seven primary isoforms (b, g, e, z, Z, t, and y), which act as adaptor proteins to stimulate protein-protein interactions and regulate the subcellular location of proteins. Several observations make 14-3-3 an attractive candidate for mediating Protein 4.1B growth suppression. First, 14-3-3 specifically associates with Protein 4.1B, but not merlin, ezrin, or radixin . Second, 14-3-3 binds within the minimal growth suppression domain of Protein 4.1B . Third, 14-3-3 proteins have been implicated in cell cycle control, signal transduction, and apoptosis (reviewed in Muslin and Xing, 2000) .
In this report, comparative binding studies were used to identify potentially important residues for the interaction of Protein 4.1B with 14-3-3. GST affinity chromatography and cointeraction experiments demonstrated that one specific mutation (F359Y) disrupts Protein 4.1B binding to 14-3-3, but does not impair binding to other known Protein 4.1B interactors, including CD44, PRMT3, and bII-spectrin. The reexpression of the F359Y mutant in two different human meningioma cell lines (IOMM-Lee and CH157-MN) resulted in reduced cell proliferation, similar to wildtype Protein 4.1B, suggesting that binding to 14-3-3 is not essential for the growth suppressor function of Protein 4.1B in meningioma.
Results

Identification of residues that mediate Protein 4.1B/14-3-3 binding
Previous collaborative studies have identified the 14-3-3 multifunctional adaptor protein as a Protein 4.1B interactor by yeast two-hybrid interaction cloning and GST affinity chromatography . To determine whether the 14-3-3 interaction is unique to Protein 4.1B or is observable with other members of the Protein 4.1 family, comparative in vitro interaction studies were performed with two additional members of the Protein 4.1 family (Protein 4.1R and 4.1G). Significant interaction with 14-3-3Z was observed with Protein 4.1B and Protein 4.1G, but not Protein 4.1R (Figure 1a) . The 14-3-3-binding region of Protein 4.1B was previously narrowed to residues P353-L390 of the N-terminal FERM domain . Homologous regions in interacting and noninteracting Protein 4.1 members were compared to the 14-3-3-binding sequence of Protein 4.1B in an attempt to identify residues potentially important for 14-3-3 binding (Figure 1b) . Three residues at positions 356, 359, and 370 are conserved in Protein 4.1B and Protein 4.1G, but not in Protein 4.1R, suggesting that these residues might be important for 14-3-3 binding. These Protein 4.1B residues were mutated to the corresponding Protein 4.1R residues using site-directed mutagenesis in a Protein 4.1B fragment, DAL-1 (Figure 1c ). The DAL-1 fragment contains residues Met 110 through Ser
853
, with a deletion of the N-and C-terminal domains as well as internal deletions within the U2 and SAB domains (Figure 1c) . We chose to use the DAL-1 fragment based on previous studies in our laboratory, which demonstrated that this fragment contains all the residues necessary for the growth suppressor function of Protein 4.1B in meningioma cells (Gutmann et al., 2001a) . Moreover, DAL-1 has been shown to interact with all known Protein 4.1B-binding partners (Gutmann et al, 2001a; Yu et al., 2002; Robb et al, 2003, Robb VA and Gutmann DH, unpublished observations) . , with a deletion of the N-and C-terminal domains as well as internal deletions within the U2 and SAB domains (S523-E709 and S728-Q739, respectively). Residues identified as potentially important for the 14-3-3 interaction were mutated by site-directed mutagenesis Role of 14-3-3 in Protein 4.1B growth suppression VA Robb et al F359Y mutation selectively abolishes DAL-1 binding to 14-3-3
To determine whether the selected DAL-1 mutants retained their ability to interact with 14-3-3, in vitro GST affinity chromatography experiments were performed using bacterial GST-14-3-3Z. Wild-type DAL-1 and the DAL-1 mutants, F356Q and H370Y, exhibited significant binding to 14-3-3Z ( Figure 2a ). In contrast, 14-3-3 binding was not observed with the F359Y DAL-1 mutant. To confirm this result, the complementary experiment was performed, in which we tested the ability of wild-type and F359Y mutant DAL-1 GST fusion proteins to interact with 14-3-3Z and 14-3-3g in vitro. In contrast to wild-type DAL-1, the F359Y DAL-1 mutant did not exhibit significant binding to either 14-3-3 isoform tested ( Figure 2b ). In addition, in vivo coimmunoprecipitation studies demonstrated that wildtype DAL-1, but not the F359Y DAL-1 mutant, interacted with 14-3-3Z and 14-3-3g (data not shown).
To evaluate binding to endogenous 14-3-3 isoforms, wild-type DAL-1 and mutant F359Y DAL-1 were tested for their ability to interact with endogenous 14-3-3 from IOMM-Lee meningioma cell lysates. Consistent with the previous results, 14-3-3 interacts with wild-type DAL-1, but binding to all 14-3-3 isoforms was abrogated with the mutant F359Y DAL-1 (Figure 2c ). Scanning densitometry demonstrated that binding to all 14-3-3 isoforms was reduced by over 700-fold in the F359Y mutant compared to wild-type DAL-1 (data not shown).
To ensure that the F359Y DAL-1 mutation did not disrupt binding to other known Protein 4.1B interactors, we analysed F359Y DAL-1 interactions with CD44, bII-spectrin, and PRMT3. GST affinity experiments demonstrated that mutant F359Y DAL-1 interacts with bII-spectrin and PRMT3, similar to wild-type DAL-1 (Figure 3a ). In addition, in vivo interaction studies demonstrated that both wild-type DAL-1 and mutant F359Y DAL-1 interacted with CD44 ( Figure 3b ). Quantitation of the binding by scanning densitometry analysis demonstrated no differences between wild-type DAL-1 and mutant DAL-1 with respect to binding to CD44, bII-spectrin, or PRMT3 (data not shown). Collectively, these data indicate that the F359Y mutation selectively abolishes the ability of DAL-1 to bind to 14-3-3 both in vitro and in vivo, without impairing binding to other known interactors of DAL-1.
F359Y mutation has no effect on DAL-1 growth suppression
Since the F359Y mutation selectively abolished the ability of DAL-1 to interact with 14-3-3, we next wished to determine whether the loss of 14-3-3 binding would abrogate DAL-1 growth suppression. To demonstrate in vivo protein expression, rat schwannoma RT4 cells were transfected with pcDNA3, pcDNA3.myc.-DAL-1, pcDNA3.myc.F356Q, pcDNA3.myc.F359Y, or pcDNA3.myc.H370Y. RT4 cells were utilized because Protein 4.1B does not function as a schwannoma tumor suppressor and overexpression does not result in reduced RT4 cell growth (Gutmann et al., 2001a) . This allows us to circumvent the negative growth regulatory effects of DAL-1 expression in IOMM-Lee and CH157-MN meningioma cells. Immunoblotting of transfected RT4 cell lysates demonstrated equivalent protein expression of wild-type DAL-1 and all three DAL-1 mutants in vivo (Figure 4a ).
To evaluate DAL-1 mutant growth suppression in meningioma cells, we initially employed clonogenic assays. In these experiments, equimolar amounts of each construct were transfected into the Protein 4.1B-negative IOMM-Lee or CH157-MN human meningioma cell lines, and colonies were selected in geneticin. We found that the expression of either wild-type or mutant Figure 2 14-3-3 binding to wild-type and mutant DAL-1 molecules. (a) GST affinity interactions were performed using GST alone or GST-14-3-3Z. The bound and supernatant fractions are shown for each representative interaction. Wild-type DAL-1 and F356Q and H370Y mutants exhibited significant binding to 14-3-3. Significant binding to either GST alone or mutant F359Y was not observed. (b) GST affinity interactions to assess wild-type and mutant F359Y DAL-1 binding to 14-3-3Z and 14-3-3g. The bound and supernatant fractions are shown for each representative interaction. Wild-type DAL-1 exhibited significant binding to 14-3-3Z and 14-3-3g. Significant binding to either GST alone or mutant F359Y was not observed. (c) Wild-type DAL-1 and the F359Y mutant were tested for their ability to interact with endogenous 14-3-3. Proteins from IOMM-Lee meningioma cell lysate pulled down with GST, GST-wild-type DAL-1, and GSTmutant F359Y were analysed by Western blot analysis with anti-14-3-3. The analysis showed that endogenous 14-3-3 was able to cointeract with GST-wild-type DAL-1, but not with GST-mutant F359Y. GST alone did not show any significant interaction with 14-3-3. The endogenous level of 14-3-3 proteins in the IOMM-Lee meningioma cell line is shown (total lysate) Role of 14-3-3 in Protein 4.1B growth suppression VA Robb et al DAL-1 resulted in a 40% reduction in colony number in both IOMM-Lee and CH157-MN meningioma cell lines (Figures 4b and c) . To confirm these results, stable expressing IOMM cell lines were generated. At least two independently isolated IOMM-Lee meningioma clones transfected with vector, wild-type DAL-1, and the F359Y DAL-1 mutant were selected. Immunoblotting of two independently isolated stable IOMM-Lee meningioma clones demonstrated equivalent protein expression of wild-type DAL-1 and F359Y mutant DAL-1 in vivo (Figure 5a ).
Cell proliferation was determined by thymidine incorporation. Stable clones of IOMM-Lee cells expressing either wild-type or F359Y mutant DAL-1 resulted in a 60% reduction in thymidine incorporation compared to vector controls (Figure 5b ). Collectively, these results suggest that a disruption in 14-3-3 binding has no effect on the ability of DAL-1 to suppress meningioma cell proliferation, and that 14-3-3 is unlikely to function as a critical mediator of Protein 4.1B growth suppression.
Discussion
One approach to defining the mechanism underlying Protein 4.1B growth regulation involves the identification of proteins that interact with Protein 4.1B and transduce its growth inhibitory signal. Similar to merlin, Protein 4.1B has been shown to interact with CD44 (Morrison et al., 2001; Robb et al., 2003) , a widely expressed cell surface hyaluronate receptor, and the cytoskeletal protein bII spectrin (Gutmann et al., 2001a; Gimm et al., 2002) . In contrast, Protein 4.1B does not interact with other known merlin-interacting proteins, including SCHIP-1 and HRS (Gutmann et al., 2001a) . The unique binding of 14-3-3 and PRMT-3 to Protein 4.1B suggested that these specific partnerships may be responsible for defining the growth regulatory function of Protein 4.1B. Protein methylation by PRMT molecules has been shown to regulate the transduction of signals to the nucleus and promote transcription (McBride and Silver, 2001 ). However, the binding site for PRMT3 was found to map outside of the Protein 4.1B minimal growth suppressor domain (Singh et al., manuscript in preparation; Robb VA and Gutmann DH, unpublished observations), making it unlikely that PRMT3 transduces the Protein 4.1B growth suppressor signal. Further work will be required to determine what role PRMT3 plays in transducing other properties previously attributed to Protein 4.1B (Gutmann et al., 2001a) .
The specific binding of 14-3-3 to Protein 4.1B, but not to Protein 4.1R, as well as the fact that 14-3-3 requires residues that map within the Protein 4.1B minimal growth suppression domain made 14-3-3 an attractive candidate for transducing the Protein 4.1B growth regulatory signal. Binding of 14-3-3 can regulate protein associations by (1) altering the ability of target proteins to form protein interactions, (2) changing the subcellular location of target proteins, and (3) affecting the intrinsic catalytic activity of target proteins (Muslin and Xing, 2000) . Among the functions attributed to 14-3-3 molecules is the regulation of signal transduction, particularly in cell survival and apoptotic pathways. In this regard, 14-3-3 binds to phosphorylated BAD and prevents BAD from translocating to the mitochondria to bind and inhibit the anti-apoptotic Bcl2 protein. The net result is an inhibition of apoptosis and promotion of cell survival. The role of 14-3-3 in apoptosis is especially interesting in light of recent reports that demonstrate that both merlin and DAL-1 overexpression result in increased programmed cell death (Charboneau et al., 2002; Schulze et al., 2002) . The 14-3-3 molecules typically bind to proteins that contain traditional consensus binding motifs, such as RSXpSXP. Using a series of FERM deletion constructs, we previously narrowed the Protein 4.1B/14-3-3-binding site to 37 residues within the FERM domain that lacks a consensus 14-3-3-binding motif . A more conventional 14-3-3-binding motif, RSSSKRY, is present at the carboxyl end of the Protein 4.1B FERM domain. However, a construct containing this motif, but lacking the 37-residue tract in the FERM domain, failed to bind 14-3-3 in vitro . Moreover, the DAL-1 F359Y mutant contains this conventional binding site, but was not able to bind to 14-3-3 both in vivo and in vitro. Collectively, these results suggest that the consensus 14-3-3-binding site was not responsible for 14-3-3 binding to Protein 4.1B. This finding is consistent with reports demonstrating the use of other nonconventional 14-3-3-binding motifs (Tzivion and Avruch, 2001 ). For example, another Protein 4.1 family member, the protein phosphatase (PP) PTPH1, has been shown to bind 14-3-3 via two C-terminal motifs, RSLSVE and RVDSEP (Zhang et al, 1997) .
Homologous regions in Protein 4.1 family members that differentially bind 14-3-3 were compared to the sequence of Protein 4.1B, and three residues within this binding site were identified as potentially important for the interaction with 14-3-3. To determine the functional significance of 14-3-3 binding to Protein 4.1B growth suppression, we utilized a mutagenesis approach to modify each of these residues to the corresponding residue in the 14-3-3 noninteractor, Protein 4.1R, in the context of the Protein 4.1B DAL-1 fragment. The mutation of phenylalanine at position 359 to tyrosine disrupted binding to 14-3-3Z and 14-3-3g as demonstrated by GST affinity chromatography in vitro and coimmunoprecipitation experiments in vivo. Moreover, incubation of wild-type and mutant DAL-1 GST fusion proteins with meningioma cell lysates revealed that, in contrast to wild-type DAL-1, the F359Y mutation abrogated DAL-1 binding to all 14-3-3 isoforms. This result is consistent with previous studies demonstrating that all 14-3-3 isoforms tested (14-3-3b, g, and Z) interact with Protein 4.1B .
Phosphorylation has also been shown to represent an important regulatory modification for proteins that interact with 14-3-3 (Tzivion and Avruch, 2001) . For example, the association between 14-3-3 and BAD is dependent on BAD serine phosphorylation. To determine whether DAL-1 binding was influenced by phosphorylation, we treated DAL-1 with PP1. We did not observe any reproducible change in 14-3-3 binding to either wild-type DAL-1 or mutant F359Y DAL-1 
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Role of 14-3-3 in Protein 4.1B growth suppression VA Robb et al molecules after protein dephosphorylation (Robb VA and Gutmann DH, unpublished observations) .
Similar to wild-type DAL-1, the F359Y DAL-1 mutant interacts with other known Protein 4.1B interactors, including PRMT3, bII-spectrin, and CD44, indicating that the F359Y mutation selectively abolishes the ability of Protein 4.1B to bind to 14-3-3. Although it is conceivable that the F359Y mutation completely disrupts FERM domain folding, several lines of evidence argue that the F359Y mutation specifically abrogates 14-3-3 binding without globally affecting FERM protein structure. First, we have demonstrated that the CD44-binding domain of DAL-1 resides between residues 328 and 352 of the FERM domain (Robb VA and Gutmann DH, unpublished studies) . The F359Y mutation is seven residues downstream of this binding site, and yet this mutant retains the ability to bind to CD44. Second, the PRMT3-binding site of DAL-1 also resides within the FERM domain (Singh et al., manuscript in preparation) and binding of DAL-1 to PRMT3 is unaffected by the F359Y mutation. Lastly, the hydropathic profile of DAL-1 indicates that F359 resides in a hydrophilic section of the protein and mutation of this residue to tyrosine would be predicted to have no discernable effect on the DAL-1 hydropathic profile. Studies are currently underway to crystallize the minimal growth suppressor domain of 4.1B to define its physical structure accurately.
Functional analysis of the F359Y DAL-1 mutant in Protein 4.1B-deficient IOMM-Lee and CH157-MN meningioma cells demonstrated that this mutant reduced colony formation, similar to wild-type DAL-1. Moreover, stable expression of mutant F359Y DAL-1 in IOMM-Lee meningioma cells reduced cellular proliferation in an equivalent manner as wild-type DAL-1. Collectively, these results argue that Protein 4.1B binding to 14-3-3 is not essential for its growth suppressor function in meningioma, and that other interacting proteins may be critical for transducing the Protein 4.1B growth inhibitory signal.
Merlin and Protein 4.1B have each been shown to bind to CD44 (Morrison et al., 2001; Robb et al, 2003) , and in the case of merlin, the transduction of NF2 growth inhibition signals from the extracellular matrix is dependent on merlin's interaction with CD44 (Morrison et al., 2001) . It is possible that Protein 4.1 growth suppressors interact with molecules like CD44 to regulate cell growth negatively, and that their unique mechanisms of action reflect specific associations with downstream protein interactors. Further work will be required to determine whether the regulated binding of Protein 4.1B to CD44 is important for Protein 4.1B growth suppression and which interacting proteins transduce its growth suppressor signal. The recent identification of another CD44-like protein, TSLC1, which associates with Protein 4.1B, suggests that additional transmembrane proteins may be involved in Protein 4.1B growth regulation (Yageta et al., 2002) . Studies are presently underway to determine how CD44 and TSLC1 function in concert with Protein 4.1 tumor suppressors to signal to specific downstream interacting proteins and regulate leptomeningeal cell proliferation relevant to meningioma development.
Materials and methods
GST fusion protein affinity chromatography
GST-14-3-3Z, GST-PRMT3, GST-bII-spectrin, and GST-DAL-1 fusion proteins were generated as described previously (Gutmann et al., 2001a; Yu et al., 2002) . Briefly, constructs were cloned into the pGEX.3X vector (Amersham Biosciences, Piscataway, NJ, USA), verified by sequencing, and transformed into DE3 (BL21)-competent cells for GST fusion protein production. Bacterial cultures were induced overnight with 0.5 mM IPTG at room temperature, lysed, and the GST fusion proteins isolated on glutathione-agarose beads (Sigma, St Louis, MO, USA) for the interaction experiments. Each fusion protein was freshly isolated for each experiment and verified by SDS-PAGE with Coomassie blue visualization. 14-3-3Z and 14-3-3g were cloned into the pcDNA4 vector as described previously . Protein 4.1R, 4.1G, 4.1B, and DAL-1 were cloned into the pcDNA3 vector and the DAL-1 mutants were generated as described below. Protein production was accomplished by the TnT method (Promega, Madison, WI, USA) according to the protocol supplied by the manufacturer. In vitro transcribed and translated proteins were synthesized in the presence of 35 S-methionine and confirmed by SDS-PAGE electrophoresis and autoradiography. In these interaction experiments, radiolabeled proteins were incubated with equimolar amounts of GST fusion proteins immobilized on glutathione beads overnight at 41C. An aliquot of the unbound fraction (1% of the total reaction) was saved and the beads were washed twice with NET buffer (25 mM Tris pH 7.5, 100 mM NaCl, 3 mM EDTA) containing 0.1% Triton X-100 and twice with NET buffer containing 0.05% Triton X-100. The entirety of the bound and the saved unbound fractions were eluted in Laemmli buffer, boiled 5 min, separated by SDS-PAGE electrophoresis, and analysed by autoradiography. In all experiments, significant binding to immobilized GST alone was not observed. Negative controls included vector alone and a Protein 4.1B construct (containing the U2 through U3 domains) that does not interact with either 14-3-3 or PRMT3. Each interaction experiment has been repeated at least three times with identical results.
Mutagenesis
Point mutations were introduced into pcDNA3.myc.DAL-1 using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions and using the following primer pairs. Mutant F356Q forward: 5 0 -ATC CGG CCG GGA GAG CAA GAA CAA TTT GAA AGC-3 0 ; reverse: 5 0 -GCT TTC AAA TTG TTC TTG CTC TCC CGG CCG G-3 0 . Mutant F359Y forward: 5 0 -GGA GAG TTT GAA CAA TAT GAA AGC ACC ATT GGG-3 0 ; reverse: 5 0 -CCC AAT GGT GCT TTC ATA TTG TTC AAA CTC TCC-3 0 . Mutant H370Y: forward: 5 0 -TTT AAG CTG CCA AAC TAT CGA GCT GCC AAG CG-3 0 ; reverse: 5 0 -CGC TTG GCA GCT CGA TAG TTT GGC AGC TTA AAC-3 0 . All constructs were sequenced in their entirety to verify the mutation.
Interaction studies
IOMM-Lee meningioma cells were lysed in PP1 buffer (50 mM Tris-HCl, 0.1 mM Na 2 EDTA, 5 mM dithiothreitol, 0.025% Tween-20, 1 mM MgCl 2 , and 0.5% Triton-X; New England Biolabs, Beverly, MA, USA) containing protease inhibitors and precleared by centrifugation. To reduce nonspecific binding, 1 mg of GST glutathione beads was added to the lysate and rotated at 41C for 2 h. The F359Y mutant was subcloned into the pGEX.4 T vector (Amersham Biosciences) verified by sequencing, and transformed into DE3 (BL21)-competent cells for GST fusion protein production. An aliquot of the supernatant (5% of the total reaction) was saved and the lysate was divided into three aliquots and equimolar amounts of GST, GST-wild type DAL-1, or GST-F359Y were added. Samples were rotated at 41C overnight, washed three times with PP1 buffer, eluted in 2 Â Laemmli sample buffer, loaded on 12% SDS-PAGE gels, and separated by electrophoresis. Proteins were transferred onto Immobilon membranes for Western blotting with a pan anti-14-3-3 antibody (K-19, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Western blots were developed using horseradish peroxidase-conjugated secondary antibodies (Sigma) and ECL chemiluminescence. This experiment was repeated three times with similar results.
To determine CD44 binding, RT4 cells were transfected with 2 mg pcDNA3.myc.DAL-1, pcDNA3.myc.F359Y, or pcDNA3.myc.U2U3 (negative control), and 1 mg of pcDNA3.-hisA.CD44. For 14-3-3 binding, RT4 cells were transfected with 2 mg pcDNA3.myc.DAL-1, pcDNA3.myc.F359Y, pcDNA3.myc.U2U3 (negative control), and 1 mg of either pcDNA4.14-3-3Z or pcDNA4.14-3-3g. After 48 h, cells were lysed in NP40 lysis buffer plus protease inhibitors. An aliquot of the supernatant (5% of the total reaction) was saved. Ni-NTA beads (Qiagen, Valencia, CA, USA) were added and samples were rotated at 41C for 2 h, washed, eluted in 2 Â Laemmli sample buffer, loaded on 12% SDS-PAGE gels, and separated by electrophoresis. Bound proteins were then identified by Western blot analysis using anti-myc antibodies (Sigma) as described above. Results were quantified by scanning densitometry analysis using Gel-Pro Analyzer 4.0 (Media Cybernetics, Silver Spring, MD, USA).
Clonogenic assay
Clonogenic assays used the well-characterized human meningioma cell lines, CH157-MN and IOMM-Lee (Lee, 1990; Tsai et al., 1995; Tsai et al., 1999) . Cells were transfected with equimolar amounts of pcDNA3.myc (vector), pcDNA3.-myc.DAL-1, pcDNA3.myc.F356Q, pcDNA3.myc.F359Y, or pcDNA3.myc.H370Y. Quadruplicate 60 mm plates for each transfection were grown for 2 weeks in the presence of geneticin. The number of colonies was counted after Crystal violet staining, with the mean and standard deviation determined for each condition. This experiment was repeated at least three times with identical results. As a control to confirm equivalent transfection efficiencies of all constructs, the clonogenic assay was repeated in RT4 schwannoma cells in which Protein 4.1B does not function as a tumor suppressor. All constructs resulted in equal number of colonies compared to control (data not shown).
Protein expression was assessed using the RT4 rat schwannoma cell line (Sherman et al., 1997) . RT4 rat schwannoma cells were transfected with pcDNA3.myc (vector), pcDNA3.-myc.DAL-1, pcDNA3.myc.F356Q, pcDNA3.myc.F359Y, or pcDNA3.myc.H370Y. After 48 h, cells were eluted in 2 Â Laemmli sample buffer, loaded on 12% SDS-PAGE gels, and separated by electrophoresis. Proteins were then identified by Western blot analysis using anti-myc antibodies as described above.
Thymidine incorporation assay
Stable expressing IOMM-Lee cell lines were established by transfection of 8 mg of pcDNA3.myc (vector), pcDNA3.myc.-DAL-1, or pcDNA3.myc.F359Y. Cells were selected in 500 mg/ ml geneticin for 2 weeks before individual clones were selected. Individual clones were chosen based on the expression of equivalent levels of wild-type or mutant DAL-1 expression, as determined by Western blot using anti-myc antibodies. Two vector-transfected clones and two clones each expressing either wild-type DAL-1 or F359Y mutant DAL-1 were selected for further analysis.
For the thymidine incorporation experiments, 10 5 cells of each cell line were plated in six wells of a 24-well plate. After 24 h, the media was changed to serum-free DMEM and incubated at 371C for 24 h. The media was aspirated and replaced with serum-free DMEM containing 1 mCi/ml 3 Hthymidine (Amersham Biosciences, Piscataway, NJ, USA) and incubated at 371C for 4 h. Cells were washed twice with PBS and solubilized in 200 mM NaOH. Counts per minute were determined in a Liquid Scintillation Beta Analyzer (Packard Instruments Co., Meridan, CT, USA), with the mean and standard deviation determined for each cell line. This experiment was repeated at least three times with similar results.
